Dysregulation of metalloproteins in ischemic heart disease patients with systolic dysfunction

Noman Khan1, Junaid Ullah1, Satwat Hashmi2

  • 1H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan.

Insights

This study identified 154 metalloproteins in pericardial fluid from ischemic heart disease (IHD) patients. Key proteins like ceruloplasmin and serotransferrin were linked to ferroptosis, a cell death pathway implicated in IHD with impaired heart function.

Area of Science:

  • Biochemistry
  • Cardiology
  • Proteomics

Background:

  • Ischemic heart disease (IHD) is a major global cause of mortality.
  • The role of metalloproteins in IHD pathogenesis remains incompletely understood.
  • Metalloproteins are crucial in various biological processes and disease states.

Purpose of the Study:

  • To investigate the role of metalloproteins in the pericardial fluid of IHD patients.
  • To compare metalloprotein profiles in patients with normal (LVEF >45) and impaired (LVEF <45) left ventricular ejection fraction.
  • To identify specific metalloproteins associated with cardiac dysfunction in IHD.

Main Methods:

  • Proteomic analysis of pericardial fluid from IHD patients using ZOOM-isoelectric focusing (IEF) and 1D SDS-PAGE.
  • Protein identification via nano-LC-ESI-MS/MS and Mascot search engine.
  • Differential expression analysis and pathway analysis (KEGG) to identify key proteins and pathways.

Main Results:

  • Identified 1082 proteins, including 154 metalloproteins, in pericardial fluid.
  • Found 12 differentially expressed metalloproteins between patient groups, with 11 up-regulated and serotransferrin down-regulated in impaired LVEF.
  • Zn-binding proteins (36.5%) and Ca-binding proteins (32.2%) were the most abundant metalloprotein types.
  • Ceruloplasmin and serotransferrin were associated with the ferroptosis pathway.

Conclusions:

  • Metalloprotein analysis revealed significant differences in pericardial fluid of IHD patients with varying LVEF.
  • Ceruloplasmin and serotransferrin are implicated in the ferroptosis pathway, potentially contributing to cardiac pathology in IHD.
  • Further research is needed to validate the role of these metalloproteins in IHD progression and systolic dysfunction.

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
18
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
15
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
25
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
16
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481